![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
http://www.biospace.com/News/repros-therapeutics-boss-steps-down-interim-ceo/445713/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
https://globenewswire.com/news-release/2017/01/30/912009/0/en/FDA-Grants-End-of-Phase-2-Meeting-to-Discuss-Phase-3-Requirements-for-Oral-Proellex-in-the-Treatment-of-Uterine-Fibroids.html
https://globenewswire.com/news-release/2016/12/19/898955/0/en/Repros-Requests-Meeting-With-FDA-to-Discuss-Phase-3-Requirements-for-Proellex-in-the-Treatment-of-Endometriosis.html
http://www.reuters.com/article/us-repros-study-idUSKCN0XB2IK